Webinar
HDFN: Realities From the Patients’ Perspective
Sep 22, 2026
Watch the webinar On-Demand HERE Duration: 1 Hour
Join us as we dive into Hemolytic Disease of the Fetus and Newborn (HDFN) and the realities that patients face every day with this preventable, treatable and survivable disease in this P.A.C.E. accredited webinar.
What You'll Learn:
- Maternal alloimmunization and HDFN
- The critical role that laboratorians play in detecting antibodies and guiding clinical care
- Lack of standardization of medical records and the confusion this causes
- Patient stories that highlight the gaps in care continuity
Disclaimer:
This educational activity is brought to you by QuidelOrtho.
The views and opinions expressed are those of the speaker. The information discussed also represents the best available information at the time of the live presentation and audiences viewing replays of this presentation, should always independently assess any government announcements, regulation or industry guideline updates relevant to the topic. This program is sponsored by QuidelOrtho, and the speaker must present information in accordance with applicable U.S. Food and Drug Administration (FDA) requirements and EU compliance requirements.
About Our Speakers:
About Our Speakers:
Bethany Weathersby
Founder and Executive Director
Allo Hope Foundation
Bethany Weathersby serves as the Executive Director at The Allo Hope Foundation. She received her BS degree in Early Childhood Education and Elementary Education at Jacksonville State University. She received her MEd degree in Curriculum and Instruction at Columbia International University and spent the next 15 years teaching ESL before transitioning into patient education and advocacy.
Bethany lives with her husband, Josh, and their five children in Tuscaloosa, AL. During her third pregnancy in 2013, Bethany was diagnosed with maternal alloimmunization (Kell antibodies) and her daughter was at risk for severe HDFN due to Bethany’s incredibly high titer. Bethany and her husband struggled to find the proactive medical care that Bethany and her unborn baby needed. Unfortunately, due to lack of monitoring and treatment, their daughter, Lucy, was stillborn just shy of 20 weeks. Determined to continue growing their family, Bethany partnered with two maternal-fetal specialists out of state who supported her throughout her next three pregnancies, helping the Weathersby's have the large family they had always wanted. In 2019, Bethany founded the Allo Hope Foundation to provide resources, support, and to improve care practices for alloimmunized women and HDFN patients.
Bethany Weathersby serves as the Executive Director at The Allo Hope Foundation. She received her BS degree in Early Childhood Education and Elementary Education at Jacksonville State University. She received her MEd degree in Curriculum and Instruction at Columbia International University and spent the next 15 years teaching ESL before transitioning into patient education and advocacy.
Bethany lives with her husband, Josh, and their five children in Tuscaloosa, AL. During her third pregnancy in 2013, Bethany was diagnosed with maternal alloimmunization (Kell antibodies) and her daughter was at risk for severe HDFN due to Bethany’s incredibly high titer. Bethany and her husband struggled to find the proactive medical care that Bethany and her unborn baby needed. Unfortunately, due to lack of monitoring and treatment, their daughter, Lucy, was stillborn just shy of 20 weeks. Determined to continue growing their family, Bethany partnered with two maternal-fetal specialists out of state who supported her throughout her next three pregnancies, helping the Weathersby's have the large family they had always wanted. In 2019, Bethany founded the Allo Hope Foundation to provide resources, support, and to improve care practices for alloimmunized women and HDFN patients.
About Our Speakers:
Molly Sherwood
Director of Research
Allo Hope Foundation
Molly R. Sherwood serves as Director of Research at the Allo Hope Foundation, a global nonprofit organization committed to elevating clinical care and supporting families affected by red cell alloimmunization and hemolytic disease of the fetus and newborn (HDFN). She received her education at Wake Forest University, majoring in sociology and evolutionary genetics. Before joining the foundation, she worked as a life sciences research consultant, offering professional services regarding clinical affairs, regulatory strategies and scientific publications. Following her personal diagnosis of red cell alloimmunization, she joined Allo Hope Foundation to oversee strategic partnerships and lead research and publishing programs. Her current priorities include establishing unified international care standards for HDFN, optimizing diagnostic workflows, clarifying the actual morbidity and mortality of this rare disease, and launching the world’s first dedicated patient registry for HDFN.
Molly R. Sherwood serves as Director of Research at the Allo Hope Foundation, a global nonprofit organization committed to elevating clinical care and supporting families affected by red cell alloimmunization and hemolytic disease of the fetus and newborn (HDFN). She received her education at Wake Forest University, majoring in sociology and evolutionary genetics. Before joining the foundation, she worked as a life sciences research consultant, offering professional services regarding clinical affairs, regulatory strategies and scientific publications. Following her personal diagnosis of red cell alloimmunization, she joined Allo Hope Foundation to oversee strategic partnerships and lead research and publishing programs. Her current priorities include establishing unified international care standards for HDFN, optimizing diagnostic workflows, clarifying the actual morbidity and mortality of this rare disease, and launching the world’s first dedicated patient registry for HDFN.
